EUVIMEDEUVIMED entdecken
Crossref

ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy

Wenjing Mo, Shujie Liu, Xiaozhi Zhao, Fayun Wei, Yuhang Li, Xinan Sheng, Wenmin Cao, Meng Ding, Wenlong Zhang, Xiaoqing Chen, Longxiyu Meng, Sheng Yao und 3 weitere

Advanced Healthcare Materials · 2023-08 · 12 (21)

DOI: 10.1002/adhm.202300191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 27.04.2023. Verfasst von Wenjing Mo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210008, China. Hauptthemen laut MEDLINE: Immunosuppression Therapy, Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Postdoctoral Research Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloid‐derived suppressor cells (MDSCs) and tumor‐associated macrophages (TAMs), two immunosuppressive myeloid components within the tumor microenvironment (TME), represent fundamental barriers in cancer immunotherapy, whereas current nanomedicines rarely exert dual modulatory roles on these cell types simultaneously. Reactive oxygen species (ROS) not only mediates MDSC‐induced immunosuppression but also triggers differentiation and polarization of M2‐TAMs. Herein, an ROS scavenging nanozyme, Zr‐CeO, with enhanced superoxide dismutase‐ and catalase‐like activities for renal tumor growth inhibition is reported. Mechanistically, intracellular ROS scavenging by Zr‐CeO significantly attenuates MDSC immunosuppression via dampening the unfolded protein response, hinders M2‐TAM polarization through the ERK and STAT3 pathways, but barely affects neoplastic cells and cancer‐associated fibroblasts. Furthermore, Zr‐CeO enhances the antitumor effect of PD‐1 inhibition in murine renal and breast tumor models, accompanied with substantially decreased MDSC recruitment and reprogrammed phenotype of TAMs in the tumor mass. Upon cell isolation, reversed immunosuppressive phenotypes of MDSCs and TAMs are identified. In addition, Zr‐CeO alone or combination therapy enhances T lymphocyte infiltration and IFN‐ γ production within the TME. Collectively, a promising strategy to impair the quantity and function of immunosuppressive myeloid cells and sensitize immunotherapy in both renal and breast cancers is provided.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunosuppression TherapyNeoplasmsAnimalsMiceReactive Oxygen SpeciesImmune ToleranceMyeloid CellsTumor MicroenvironmentImmunotherapy

Stichwörter der Autor:innen

cancer immunotherapyimmune checkpoint blockade therapymyeloid-derived suppressor cellsnanozymestumor-associated macrophages

Substanzen

Reactive Oxygen Species

Autor:innen und Institutionen

  • Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210008, China.
  • Department of Urology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Institute of Urology Nanjing University, 321 Zhongshan Rd, Nanjing, Jiangsu, 210008, China.
  • Department of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing National Laboratory of Microstructures, Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, Nanjing,…
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Shanghai Junshi Biosciences Co., Ltd., 200126, Shanghai, China.
  • TopAlliance Biosciences, Inc., Rockville, MD, 20850, USA.

ORCID-Profile: Hui Wei

Förderung

  • National Natural Science Foundation of China
  • Postdoctoral Research Foundation of China

Zitieren

APA

Mo, W., Liu, S., Zhao, X., Wei, F., Li, Y., Sheng, X., Cao, W., Ding, M., Zhang, W., Chen, X., Meng, L., Yao, S., Diao, W., Wei, H., & Guo, H. (2023). ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy. Advanced Healthcare Materials, 12(21). https://doi.org/10.1002/adhm.202300191

Vancouver

Mo W, Liu S, Zhao X, Wei F, Li Y, Sheng X, et al. ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy. Advanced Healthcare Materials. 2023;12(21). doi:10.1002/adhm.202300191

BibTeX
@article{Mo2023,
  author = {Mo, Wenjing and Liu, Shujie and Zhao, Xiaozhi and Wei, Fayun and Li, Yuhang and Sheng, Xinan and Cao, Wenmin and Ding, Meng and Zhang, Wenlong and Chen, Xiaoqing and Meng, Longxiyu and Yao, Sheng and Diao, Wenli and Wei, Hui and Guo, Hongqian},
  title = {ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy},
  journal = {Advanced Healthcare Materials},
  year = {2023},
  volume = {12},
  number = {21},
  doi = {10.1002/adhm.202300191}
}
Kostenlos starten →